PRostate Cancer Plasma Integrative Multi-modal Evaluation

Plain-language summary

This study examines a multi-modal plasma evaluation, including analysis of cell-free DNA and extracellular vesicles in the blood, in patients with prostate cancer. It enrolls patients diagnosed with prostate cancer who are eligible for drug treatment. This non-phase study is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Santa Chiara Hospital

Intervention

Analysis of cell free DNA, and extracellular vesicles (EVs) and EV-associated molecular components (including RNA, DNA, proteins)

Start date

5/7/2019

Estimated completion

1/31/2027

Countries

Italy

Related genes

Locations

• Meldola, Italy
• Orbassano, Italy
• Padova, Italy
• Trento, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of prostate cancer
* Eligible for prostate cancer pharmacological treatment
* Given consent to study participation

Exclusion Criteria:

\- Histological diagnosis other than prostate cancer